Jonathan Mcneill Sells Shares of CBIO $CBIO
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jonathan Mcneill, President and COO at Crescent Biopharma, Inc. ($CBIO), sold 20,549 shares at an average price of $17.99, for a total transaction of $369,676.51. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Crescent Biopharma, Inc. Stock Down 1.4%
Shares of Crescent Biopharma, Inc. ($CBIO) traded around $17.50 on Wednesday, down 1.4% for the day.
Crescent Biopharma, Inc. Earnings
Analysts Set New Price Targets
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Get Crescent Biopharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.